Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2015 | Pages:
701 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2015', provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 7 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview 8 Therapeutics Development 9 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Development by Companies 11 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes 19 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Products Glance 21 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Development by Companies 25 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Investigation by Universities/Institutes 34 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development 36 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Assessment 123 Drug Profiles 142 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Recent Pipeline Updates 450 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects 667 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products 672 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Product Development Milestones 674 Appendix 682
List of Tables
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H2 2015 27 Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis, H2 2015 28 Number of Products under Development by Companies, H2 2015 30 Number of Products under Development by Companies, H2 2015 (Contd..1) 31 Number of Products under Development by Companies, H2 2015 (Contd..2) 32 Number of Products under Development by Companies, H2 2015 (Contd..3) 33 Number of Products under Development by Companies, H2 2015 (Contd..4) 34 Number of Products under Development by Companies, H2 2015 (Contd..5) 35 Number of Products under Development by Companies, H2 2015 (Contd..6) 36 Number of Products under Investigation by Universities/Institutes, H2 2015 38 Comparative Analysis by Late Stage Development, H2 2015 39 Comparative Analysis by Clinical Stage Development, H2 2015 40 Comparative Analysis by Early Stage Development, H2 2015 41 Comparative Analysis by Unknown Stage Development, H2 2015 42 Products under Development by Companies, H2 2015 43 Products under Development by Companies, H2 2015 (Contd..1) 44 Products under Development by Companies, H2 2015 (Contd..2) 45 Products under Development by Companies, H2 2015 (Contd..3) 46 Products under Development by Companies, H2 2015 (Contd..4) 47 Products under Development by Companies, H2 2015 (Contd..5) 48 Products under Development by Companies, H2 2015 (Contd..6) 49 Products under Development by Companies, H2 2015 (Contd..7) 50 Products under Development by Companies, H2 2015 (Contd..8) 51 Products under Investigation by Universities/Institutes, H2 2015 52 Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 53 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by 4SC AG, H2 2015 54 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AbbVie Inc., H2 2015 55 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Actinium Pharmaceuticals, Inc., H2 2015 56 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Affimed Therapeutics AG, H2 2015 57 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Altor BioScience Corporation, H2 2015 58 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Amgen Inc., H2 2015 59 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Ariad Pharmaceuticals, Inc., H2 2015 60 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Array BioPharma Inc., H2 2015 61 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Astex Pharmaceuticals, Inc., H2 2015 62 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AstraZeneca Plc, H2 2015 63 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Atara Biotherapeutics, Inc., H2 2015 64 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Baxalta Incorporated, H2 2015 65 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015 66 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bexion Pharmaceuticals, LLC., H2 2015 67 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bio-Path Holdings, Inc., H2 2015 68 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by BioSight Ltd., H2 2015 69 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bristol-Myers Squibb Company, H2 2015 70 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Calithera Biosciences, Inc., H2 2015 71 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cantargia AB, H2 2015 72 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Celator Pharmaceuticals, Inc., H2 2015 73 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellectis S.A., H2 2015 74 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellular Biomedicine Group, Inc., H2 2015 75 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Ceronco Biosciences, H2 2015 76 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Constellation Pharmaceuticals, Inc., H2 2015 77 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015 78 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 79 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by DiNonA Inc., H2 2015 80 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Effimune SAS, H2 2015 81 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Eli Lilly and Company, H2 2015 82 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015 83 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by EpiZyme, Inc., H2 2015 84 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Erytech Pharma SA, H2 2015 85 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Eureka Therapeutics, Inc., H2 2015 86 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Fate Therapeutics, Inc., H2 2015 87 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Formula Pharmaceuticals, Inc., H2 2015 88 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Gamida Cell Ltd., H2 2015 89 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by GlaxoSmithKline Plc, H2 2015 90 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Hangzhou Minsheng Pharmaceutical Group Co.,Ltd, H2 2015 91 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by iDD biotech SAS, H2 2015 92 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Immunomedics, Inc., H2 2015 93 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Incyte Corporation, H2 2015 94 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Interprotein Corporation, H2 2015 95 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Jasco Pharmaceuticals, LLC., H2 2015 96 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Johnson & Johnson, H2 2015 97 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Juno Therapeutics Inc., H2 2015 98 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2015 99 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 100 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Kiadis Pharma B.V., H2 2015 101 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Kite Pharma, Inc., H2 2015 102 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by medac GmbH, H2 2015 103 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by MedImmune, LLC, H2 2015 104 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Merck & Co., Inc., H2 2015 105 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 106 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Mirna Therapeutics, Inc., H2 2015 107 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Nanovalent Pharmaceuticals Inc., H2 2015 108 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by NantKwest, Inc., H2 2015 109 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Novartis AG, H2 2015 110 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by NovImmune SA, H2 2015 111 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by NuCana BioMed Limited, H2 2015 112 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Omeros Corporation, H2 2015 113 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Onconova Therapeutics, Inc., H2 2015 114 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015 115 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Oribase Pharma, H2 2015 116 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pfenex Inc., H2 2015 117 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pfizer Inc., H2 2015 118 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pharma Mar, S.A., H2 2015 119 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Polyphor Ltd., H2 2015 120 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Portola Pharmaceuticals, Inc., H2 2015 121 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Priaxon AG, H2 2015 122 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Quimatryx, S.L., H2 2015 123 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Red5 Pharmaceuticals, LLC, H2 2015 124 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sanofi, H2 2015 125 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sareum Holdings Plc, H2 2015 126 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Seattle Genetics, Inc., H2 2015 127 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sellas Inc., H2 2015 128 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sorrento Therapeutics, Inc., H2 2015 129 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015 130 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Syndax Pharmaceuticals, Inc., H2 2015 131 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Syros Pharmaceuticals, Inc., H2 2015 132 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by TetraLogic Pharmaceuticals, H2 2015 133 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Theravectys SA, H2 2015 134 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015 135 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Tolero Pharmaceuticals, Inc., H2 2015 136 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Tragara Pharmaceuticals, Inc., H2 2015 137 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Verastem, Inc., H2 2015 138 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Xbrane Bioscience AB, H2 2015 139 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Xenetic Biosciences plc, H2 2015 140 Assessment by Monotherapy Products, H2 2015 141 Assessment by Combination Products, H2 2015 142 Number of Products by Stage and Target, H2 2015 144 Number of Products by Stage and Mechanism of Action, H2 2015 151 Number of Products by Stage and Route of Administration, H2 2015 157 Number of Products by Stage and Molecule Type, H2 2015 159 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics - Recent Pipeline Updates, H2 2015 468 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects, H2 2015 685 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects (Contd..1), H2 2015 686 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects (Contd..2), H2 2015 687 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects (Contd..3), H2 2015 688 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects (Contd..4), H2 2015 689 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products, H2 2015 690 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products (Contd..1), H2 2015 691
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
